Form 4: Heron Therapeutics Executive Exercises Stock Options
SEC Form 4
William P. Forbes, EVP and Chief Development Officer of Heron Therapeutics, exercised stock options and reported changes in beneficial ownership.
Summary
- On October 19, 2024, William P. Forbes, the EVP and Chief Development Officer of Heron Therapeutics, exercised stock options.
- This transaction involved the acquisition of 3,874 shares of common stock.
- Following the transaction, Forbes directly owns 103,123 shares of Heron Therapeutics common stock.
- Forbes also holds 50,366 restricted stock units.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard Form 4 filing indicating an executive exercising stock options. It doesn't inherently suggest positive or negative implications for the company.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This filing indicates that a key executive is exercising their options, which is a common occurrence.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the increase in outstanding shares, but it's unlikely to be significant.
Key Dates
| Date | Description |
|---|---|
| 01/19/2024 | Date of grant for restricted stock units, which vest in 16 equal quarterly installments beginning one quarter after this date. |
| 10/19/2024 | Date of transaction: William P. Forbes exercised stock options and acquired 3,874 shares of common stock. |
| 10/21/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.